233 related articles for article (PubMed ID: 26971630)
1. Combinatorial Antigen Targeting: Ideal T-Cell Sensing and Anti-Tumor Response.
Themeli M; Sadelain M
Trends Mol Med; 2016 Apr; 22(4):271-273. PubMed ID: 26971630
[TBL] [Abstract][Full Text] [Related]
2. A Receptor for All Occasions.
Irvine DJ
Cell; 2016 Feb; 164(4):599-600. PubMed ID: 26871625
[TBL] [Abstract][Full Text] [Related]
3. SYNTHETIC BIOLOGY. Customizing cell-cell communication.
Vogt N
Nat Methods; 2016 Apr; 13(4):285. PubMed ID: 27482567
[No Abstract] [Full Text] [Related]
4. Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors.
Morsut L; Roybal KT; Xiong X; Gordley RM; Coyle SM; Thomson M; Lim WA
Cell; 2016 Feb; 164(4):780-91. PubMed ID: 26830878
[TBL] [Abstract][Full Text] [Related]
5. Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits.
Roybal KT; Rupp LJ; Morsut L; Walker WJ; McNally KA; Park JS; Lim WA
Cell; 2016 Feb; 164(4):770-9. PubMed ID: 26830879
[TBL] [Abstract][Full Text] [Related]
6. NOTCH Signaling in T-Cell-Mediated Anti-Tumor Immunity and T-Cell-Based Immunotherapies.
Kelliher MA; Roderick JE
Front Immunol; 2018; 9():1718. PubMed ID: 30967879
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor T Cells: Self-Replicating Drugs for Cancer.
Melenhorst JJ; Lacey SF; Bedoya F
Curr Drug Targets; 2017; 18(3):332-340. PubMed ID: 26302796
[TBL] [Abstract][Full Text] [Related]
8. Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors.
Roybal KT; Williams JZ; Morsut L; Rupp LJ; Kolinko I; Choe JH; Walker WJ; McNally KA; Lim WA
Cell; 2016 Oct; 167(2):419-432.e16. PubMed ID: 27693353
[TBL] [Abstract][Full Text] [Related]
9. T Cell Engineering.
Pircher M; Schirrmann T; Petrausch U
Prog Tumor Res; 2015; 42():110-35. PubMed ID: 26383243
[TBL] [Abstract][Full Text] [Related]
10. Engineering of an enhanced synthetic Notch receptor by reducing ligand-independent activation.
Yang ZJ; Yu ZY; Cai YM; Du RR; Cai L
Commun Biol; 2020 Mar; 3(1):116. PubMed ID: 32170210
[TBL] [Abstract][Full Text] [Related]
11. Biologics: Engineering T cells for customized therapeutic responses.
Kingwell K
Nat Rev Drug Discov; 2016 Nov; 15(12):819. PubMed ID: 27895334
[No Abstract] [Full Text] [Related]
12. Chimeric antigen receptors: driving immunology towards synthetic biology.
Sadelain M
Curr Opin Immunol; 2016 Aug; 41():68-76. PubMed ID: 27372731
[TBL] [Abstract][Full Text] [Related]
13. Synthetic Biology Approaches in Immunology.
Mohammad NB; Lam CCK; Truong K
Biochemistry; 2019 Mar; 58(11):1484-1491. PubMed ID: 30481004
[TBL] [Abstract][Full Text] [Related]
14. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
[TBL] [Abstract][Full Text] [Related]
15. Inducible Gene Switches with Memory in Human T Cells for Cellular Immunotherapy.
Chakravarti D; Caraballo LD; Weinberg BH; Wong WW
ACS Synth Biol; 2019 Aug; 8(8):1744-1754. PubMed ID: 31268301
[TBL] [Abstract][Full Text] [Related]
16. Engineering advanced cancer therapies with synthetic biology.
Wu MR; Jusiak B; Lu TK
Nat Rev Cancer; 2019 Apr; 19(4):187-195. PubMed ID: 30837696
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
18. Viral Engineering of Chimeric Antigen Receptor Expression on Murine and Human T Lymphocytes.
Hammill JA; Afsahi A; Bramson JL; Helsen CW
Methods Mol Biol; 2016; 1458():137-57. PubMed ID: 27581020
[TBL] [Abstract][Full Text] [Related]
19. T-cell engineering for cancer immunotherapy.
Sadelain M
Cancer J; 2009; 15(6):451-5. PubMed ID: 20010162
[TBL] [Abstract][Full Text] [Related]
20. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells.
Kloss CC; Condomines M; Cartellieri M; Bachmann M; Sadelain M
Nat Biotechnol; 2013 Jan; 31(1):71-5. PubMed ID: 23242161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
